Wyeth is one of the world's largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of prescription drugs and over-the-counter medications. It is also a global leader in vaccines, biotechnology and animal health care.
References
1. Moots R et al. Patterns of dose escalation and DMARD intensification in 739 patients with rheumatoid arthritis (RA) treated with anti-TNF agents (ATAs): Results from the DART study. Presented at the British Society of Rheumatology annual meeting, 24 April 2008, Liverpool, UK; Abstract 418
2. Bartelds GM et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007 Jul;66(7):921-6
3. van der Laken CJ et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007 Feb;66(2):253-6
4. Wolbink GJ et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005 May;64(5):704-7
5. Remicade(R) (infliximab) EMEA SPC: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/H-240.... Last accessed 16 April 2008
6. Humira(R) (adalimumab) EMEA SPC. http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/H-481-P.... Last accessed 16 April 2008
7. Enbrel EMEA SPC. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-P...) Last accessed 14 April 2008
To register for further media information relating to this press release and future media announcements, please log on to the media centre at http://www.wyeth.eu.
For further information, please contact: Wyeth: Gill Markham, Communications - Europe, Middle East and Africa, Direct Tel: +44(0)1628-692536, Email: markhagl@wyeth.com; OgilvyHealthPR: Karen Crum, Direct Tel: +44(0)207-108-6411, Email: karen.crum@ohpr.com; Jodi Lewis, Direct Tel: +44(0)207-108-6086, Email: jodi.lewis@ohpr.com